title: Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
abstract: OBJECTIVE
  Partial splenic embolization (PSE) is a non-surgical alternative for the treatment of hypersplenism. Thrombocytopenia precludes the use of pegylated interferon (peg-IFN) and ribavirin in cirrhotic patients with hepatitis C virus (HCV). We aimed to evaluate the role of PSE as a procedure allowing combined HCV therapy in this setting.
  
  
  METHODS
  A retrospective analysis of the safety and rate of sustained virological response (SVR) after a full-dose course of peg-IFN plus ribavirin in eight HCV cirrhotic patients with severe hypersplenism undergoing PSE at a tertiary centre in Madrid, Spain, from May 2002 to August 2004.
  
  
  RESULTS
  Six patients (75%) were in Child-Pugh class B (median score 7). PSE significantly improved the mean platelet (P = 0.012), leucocyte (P = 0.017) and haemoglobin (P = 0.035) levels, and prothrombin activity (P = 0.012). After a mean of 20 weeks after PSE all patients started weight-adjusted ribavirin plus peg-IFN-alpha2b (n = 6) or 180 microg/week of peg-IFN-alpha2a (n = 2). Six subjects (75%) completed therapy with no peg-IFN dose reductions; the dose of ribavirin was reduced in two patients reaching haemoglobin levels of less than 10 g/dl (one also received erythropoietin and granulocyte colony-stimulating factor because of neutrophil counts < 300 cells/microl). Three patients (38%) achieved SVR. Portal vein thrombosis was observed in 50% of patients, but did not preclude antiviral therapy. The pathogenic mechanism was multifactorial. It was successfully managed with anticoagulant therapy in two cases.
  
  
  CONCLUSIONS
  PSE allowed the safe use of peg-IFN plus ribavirin in HCV cirrhotic patients with severe cytopenias who otherwise would never have been treated. The rate of SVR was 38%.
authors.affiliation: Department of Hepatology and Gastroenterology, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: José R
authors.initials: JR
authors.lastname: Foruny
authors.forename: Javier
authors.initials: J
authors.lastname: Blázquez
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Rafael
authors.initials: R
authors.lastname: Bárcena
authors.forename: Luis
authors.initials: L
authors.lastname: Gil-Grande
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: María J
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: Javier
authors.initials: J
authors.lastname: Moreno
authors.forename: Juan
authors.initials: J
authors.lastname: Sánchez
authors.forename: Alfonso
authors.initials: A
authors.lastname: Muriel
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Rodriguez-Sagrado
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006971:Hypersplenism / Q000209:etiology / Q000628:therapy*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000821:virology; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a